EPISODE · May 19, 2026 · 3 MIN
今天3分钟我们来聊聊卵巢癌复发新希望！三药联用创奇迹
from 源于细胞BioInsid的个人播客
卵巢癌复发难治，铂类耐药患者中位生存期不足12个月。美国研究用Ampligen、Keytruda和顺铂三药联合治疗24名难治患者，客观缓解率50%，5人完全缓解，中位总生存期达32.5个月，最长缓解超6年，为患者带来新曙光。参考文献：AIM ImmunoTech新闻稿（2026年5月7日）ClinicalTrials.gov NCT03734692UPMC Magee-Womens Hospital II期临床试验数据前往小宇宙评论区与主播互动
Embed this episode
Ready to play
今天3分钟我们来聊聊卵巢癌复发新希望！三药联用创奇迹
0:00
3:27
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of 源于细胞BioInsid的个人播客?
This episode is 3 minutes long.
When was this 源于细胞BioInsid的个人播客 episode published?
This episode was published on May 19, 2026.
Can I download this 源于细胞BioInsid的个人播客 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!